FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to immune therapy, and can be used to assess the efficacy of treating the patients suffering cancer. That is ensured by administering an immunogenic composition, which contains a recombinant viral vector expressing in vivo the whole MUC-1 antigen or a portion thereof. A method for analysing preparing a biological sample from a patient after the above immunogenic composition has been introduced, and measuring interferon γ in the sample. If interferon γ is more than approximately 4 pg/ml the patient is suggested to show the favourable clinical outcome.
EFFECT: invention assessing the clinical response to the cancer treatment in the patient.
15 cl, 3 dwg, 1 ex
